TrialJournal for immunotherapy of cancer2021

Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial.

Yoland Antill et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.